Education
About Us
Working with TipRanks
Follow Us
DaVita (DVA)
NYSE:DVA
DVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$125.64 - $179.60
Previous CloseN/A
Volume85.32K
Average Volume (3M)961.19K
Market Cap
$12.30B
Enterprise Value$25.65B
Total Cash (Recent Filing)$755.91M
Total Debt (Recent Filing)$3.64B
Price to Earnings (P/E)13.9
Beta0.56
Next Earnings
May 13, 2025EPS Estimate
2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.74
Shares Outstanding80,000,000
10 Day Avg. Volume697,723
30 Day Avg. Volume961,194
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)N/A
Price to Sales (P/S)0.92
Price to Cash Flow (P/CF)5.40
P/FCF Ratio6.40
Enterprise Value/Market Cap2.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.00
Enterprise Value/Ebitda9.34
Forecast
1Y Price Target
$172.00Price Target Upside15.06% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
DaVita News
PremiumCompany Announcements
DaVita’s Earnings Call: Balancing Growth and Challenges
PremiumThe Fly
DaVita falls -14.7%---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe price target for DaVita's stock has been increased to $165, reflecting confidence in future performance.
Operational EfficiencyInclusion of oral phosphate binders is expected to provide a potential operating income benefit, with the midpoint considered most likely.
Bears Say
Cost ManagementDaVita expects revenue per treatment growth of 4.5% to 5.5% and cost per treatment growth of 6% to 7%, driven significantly by oral phosphate binders.
Earnings GuidanceManagement provided 2025 guidance including EBIT forecast below consensus and flat total treatment volume.
Volume Growth ChallengesDVA experienced pressure on treatment volumes in the quarter from hurricanes.
---
Ownership Overview
45.61% Insiders
10.35% Mutual Funds
6.34% Other Institutional Investors
21.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DVA FAQ
What was DaVita’s price range in the past 12 months?
DaVita lowest stock price was $125.64 and its highest was $179.60 in the past 12 months.
What is DaVita’s market cap?
DaVita’s market cap is $12.30B.
When is DaVita’s upcoming earnings report date?
DaVita’s upcoming earnings report date is May 13, 2025 which is in 37 days.
How were DaVita’s earnings last quarter?
DaVita released its earnings results on Feb 13, 2025. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.126 by $0.114.
Is DaVita overvalued?
According to Wall Street analysts DaVita’s price is currently Undervalued.
Does DaVita pay dividends?
DaVita does not currently pay dividends.
What is DaVita’s EPS estimate?
DaVita’s EPS estimate is 2.03.
How many shares outstanding does DaVita have?
DaVita has 80,000,000 shares outstanding.
What happened to DaVita’s price movement after its last earnings report?
DaVita reported an EPS of $2.24 in its last earnings report, beating expectations of $2.126. Following the earnings report the stock price went down -11.092%.
Which hedge fund is a major shareholder of DaVita?
Currently, no hedge funds are holding shares in DVA
---
DaVita Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$172.00 (15.06% Upside)
$172.00 (15.06% Upside)
Blogger Sentiment
Bullish
DVA Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 293.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.44%
12-Months-Change
Fundamentals
Return on Equity
159.08%
Trailing 12-Months
Asset Growth
2.00%
Trailing 12-Months
Company Description
DaVita
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
---
DVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While DaVita Inc. showed strong financial performance and pursued strategic growth initiatives such as the Latin America expansion and transitioning oral drugs, challenges with volume growth, disruptions caused by Hurricane Helene, and international income declines present significant concerns. The sentiment is balanced with achievements in certain areas and setbacks in others.Read More>---
DVA Revenue Breakdown
88.32% U.S. dialysis
11.68% Ancillary services
---
DVA Stock 12 Month Forecast
Average Price Target
$172.00
▲(15.06% Upside)
Technical Analysis
Community Health
―
Fresenius Medical Care
―
HCA Healthcare
―
Tenet Healthcare
―
Universal Health
―
Best Analysts Covering DVA
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-5.80%
assigned a sell rating 5 months ago
Copying Joanna Gajuk's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -5.80% per trade.
---